Qkine is a Cofinitive #21toWatch Top21.2023 winner!
Qkine is excited to be a Top21.2023 winner in this year’s Cofinitive #21toWatch awards.
3
03, 2023
15
12, 2022
Qkine raises over £4M to scale manufacturing, R&D and commercial functions
Qkine Ltd, a manufacturer of animal-free, highly bioactive, and innovative proteins and growth factors for life science applications, announces the close of its oversubscribed funding raise, having secured £4.3M.
23
11, 2022
Qkine and 3D Bio-Tissues collaboration awarded €100,000 at EIT Food Venture Summit 2022
A collaboration between Qkine and 3D Bio-Tissues has been awarded one of four prestigious prizes at the 2022 EIT Food Venture Summit, held in Lisbon, Portugal. Prize money will be used to develop new solutions to reduce the cost of cultivated meat.
1
08, 2022
Qkine secures lease on new premises to scale up manufacture
Qkine secure a new lease on premises based in Cambridge city centre. The building will be transformed into modern agile lab and office spaces for research and process development, plus a dedicated, beta lactam free state of the art manufacturing suite.
11
03, 2022
List prices frozen until 2023
Despite the ongoing challenges faced by the whole industry, we are demonstrating our commitment to supporting stem cell researchers by freezing our prices until January 1st, 2023. Furthermore, we will include free shipping on all orders moving forward.
10
09, 2021
Qkine earns ISO 9001:2015 certification for protein R&D and manufacture facilities in Cambridge, UK
Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.
26
07, 2021
Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®
Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.
21
07, 2020
Rob Nixon joins Qkine as Head of Commercial and Dr Cassie Doherty is appointed to the board
Cambridge, UK 21 July 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – is delighted to announce the appointment of Rob Nixon to its management team as Head of Commercial and Dr Cassie Doherty, Investment Director at Parkwalk, to its board. With years of [...]
8
06, 2020
Qkine secures £1.5M series A funding from leading life science investors
Qkine secures £1.5M series A funding from leading life science investors Cambridge, UK 08 June 2020: Qkine – a specialist developer and manufacturer of proteins for stem cell, organoid and regenerative medicine applications – today announced the successful closure of a £1.5M series A investment round to accelerate the global [...]
3
06, 2019
Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio
Qkine secures additional £550K to extend development of R&D pipeline and accelerate commercialisation of product portfolio Cambridge, UK 03 June 2019: Qkine, specialist manufacturer of proteins for stem cell, organoid and regenerative medicine applications, has closed a further round of investment. The £550K funding round was led by Cambridge Enterprise [...]
